Real‑life cost and cost‑effectiveness for tiotropium 18 μg od monotherapy in moderate and severe COPD patients: a 48‑month survey

Real‑life cost and cost‑effectiveness for tiotropium 18 μg od monotherapy in moderate and severe COPD patients: a 48‑month survey

BACKGROUND: Tiotropium monotherapy enables a significant minimization of morbidity in COPD. OBJECTIVE: to evaluate and compare cost and cost‑effectiveness of tiotropium monotherapy administrated for 24 months (18 μg od) in mild‑to‑moderate and severe chronic obstructive pulmonary disease (COPD). MET...

Full description

Bibliographic Details
Main Authors: Massimiliano Povero, Lorenzo Pradelli, Paola Turco, Roberto Walter Dal Negro
Format: Article
Language:English
Published: SEEd Medical Publishers 2014-06-01
Series:Farmeconomia: Health Economics and Therapeutic Pathways
Subjects:
copd
cost-effectiveness
tiotropium
Online Access:https://journals.seedmedicalpublishers.com/index.php/FE/article/view/924

Internet

https://journals.seedmedicalpublishers.com/index.php/FE/article/view/924

Similar Items